Relapse After Quitting: What Predicts It and What to Do

Relapse after quitting smoking is the norm, not the exception. Population data shows that most quit attempts end in relapse, and the relapse curve is steepest in the first week [1]. Understanding the pattern, the predictors and the response options turns each attempt into information that improves the next one.

When relapse happens

The timing is consistent across studies [1]:

• Days 1-7: Highest relapse risk. Withdrawal symptoms peak during this window, and the behavioral disruption of the first smoke-free days is greatest. Roughly a third of all relapse events in clinical studies occur in this single week.
• Weeks 2-4: Risk remains high but decreasing. Withdrawal symptoms are moderating but still present. Situational triggers begin to emerge as the acute withdrawal fog lifts and the person re-encounters their normal routine without smoking.
• Months 2-3: A secondary risk period, often driven by situations (social events, stress episodes, alcohol consumption) rather than baseline withdrawal. The smoker has adjusted to daily life without cigarettes but has not yet encountered every high-risk situation.
• Months 3-12: Relapse continues but at a lower rate. Individual triggers (major life stress, alcohol, weight gain, a belief that “one won’t hurt”) drive most late relapses.
• After 12 months: Risk continues to decrease with time but never fully reaches zero. Long-term ex-smokers occasionally relapse years later, usually triggered by a major life stressor or by returning to an environment strongly associated with their former smoking behavior.

The practical implication: pharmacological support during the first 8-12 weeks covers the highest-risk period, and extended use (24 weeks) covers the secondary risk period. The relapse curve explains why standard treatment durations exist and why extending them helps.

What predicts relapse

A systematic review identified consistent predictors across studies [5]:

Nicotine dependence level. Higher dependence (measured by time to first cigarette, cigarettes per day, or Fagerstrom score) predicts relapse. This is pharmacological: heavier dependence means more intense withdrawal, which drives early relapse. The appropriate response is higher-efficacy pharmacotherapy, not more willpower. A smoker who scores 7+ on the Fagerstrom scale and attempts to quit with a single 14 mg patch is pharmacologically set up for relapse before the quit date arrives.

Negative mood. Stress, anxiety, depression and frustration are the most commonly reported triggers for both initial lapses and full relapse [3]. Nicotine provides a rapid (10-20 second) dopamine response that temporarily reduces negative affect. After quitting, the first encounter with significant stress or low mood in the absence of this response is a high-risk moment. The association between negative affect and relapse is strong enough that smokers with a history of depression have lower quit rates, and bupropion (which treats both depression and nicotine dependence) may be particularly appropriate for this group.

The negative mood trigger is also the most commonly misinterpreted. Smokers often describe relapse in terms of specific life events (“I was going through a divorce,” “I lost my job”), which frames the relapse as situationally inevitable. The evidence suggests it is pharmacologically mediated: the stressor created negative affect, and the absence of nicotine’s affect-regulating effect made the craving intolerable. The same stressor, experienced with adequate pharmacological support, is less likely to cause relapse.

Alcohol use. Alcohol reduces inhibitory control and is strongly associated with smoking in behavioral memory. Many smokers report that their first lapse occurred while drinking [3]. The association is bidirectional: alcohol triggers craving through conditioned association, and it simultaneously reduces the cognitive control that resists the craving. Avoiding alcohol in the first month of a quit attempt is one of the most practical and underutilized relapse prevention strategies.

Social exposure. Living with a smoker, socializing with smokers, and being in environments where smoking is visible and normalized all increase relapse risk. The mechanism is both cue-triggered craving (seeing and smelling cigarettes activates the conditioned response) and social facilitation (the perceived acceptability of smoking in a group of smokers reduces the psychological barrier to taking a cigarette). Partners who smoke are a particularly strong predictor: quitting when your partner does not is measurably harder.

Inadequate pharmacological support. Unassisted quit attempts and underdosed NRT are associated with higher relapse rates. This is one of the most modifiable predictors. A smoker who has relapsed on cold turkey and then relapsed again on cold turkey is not demonstrating inability to quit; they are demonstrating that their dependence level requires pharmacological support.

Prior quit attempt history. Counterintuitively, the number of prior failed attempts does not strongly predict failure on the next one, once the method is accounted for. What matters is whether the next attempt addresses what caused the previous relapse. A person with five failed cold-turkey attempts who tries varenicline for the first time is not meaningfully disadvantaged by their history.

The slip-to-relapse progression

A single cigarette (a “lapse” or “slip”) does not automatically mean full relapse, but the odds of progression are high. Real-time monitoring studies found that most lapses progress to full relapse within days [3]. The mechanism is partly pharmacological: a single dose of nicotine reactivates receptor-mediated craving, producing an intensified desire for the next cigarette that did not exist before the slip. It is partly psychological: the “abstinence violation effect,” where a slip is interpreted as evidence that quitting has failed, that the person “doesn’t have what it takes,” which removes the psychological commitment to abstinence that was restraining use.

The distinction between a slip and a relapse matters because the intervention is different. After a slip, the optimal response is immediate return to abstinence: discard any remaining cigarettes, continue or resume pharmacological support, identify what triggered the slip, and treat it as a data point rather than a verdict. After a full relapse (return to regular smoking), the intervention is a new quit attempt with adjustments based on what happened.

Continuing pharmacological support through a slip is important and often counterintuitive. People who slip while on the patch often remove the patch, reasoning that it “isn’t working.” The patch was maintaining reduced craving and withdrawal suppression; removing it after a slip adds full withdrawal on top of the demoralization of the slip, making full relapse more likely. The correct response is to keep the patch on, use gum or lozenge for the acute craving, and return to abstinence.

What reduces relapse

The Cochrane review of relapse prevention interventions found [2]:

Strategy	Evidence for relapse prevention	Key study
Extended pharmacotherapy (24+ weeks)	Supported; reduces late relapse	Tonstad 2006 (varenicline)
Higher-efficacy initial method	Supported; lower relapse rates with combination NRT and varenicline	Cochrane NRT review
Behavioral skills training	Mixed; some benefit for identifying and managing triggers	Cochrane relapse prevention review
Combination NRT from the start	Supported; reduces both early and late relapse	Cochrane NRT review
Alcohol avoidance in early abstinence	Supported by observational data	Agboola 2015 systematic review
Financial incentives	Effective during incentive period; less clear after removal	Multiple trials
Motivational counseling	Limited additional benefit over pharmacotherapy alone	Cochrane relapse prevention review

Extended varenicline use (24 weeks vs. 12 weeks) reduced relapse rates in a dedicated trial [4]. This supports the principle that pharmacological coverage should extend through the high-relapse period, which lasts longer than the standard 8-12 week treatment course for many people. The Cochrane review also found evidence for extended NRT as a relapse prevention strategy [2].

The evidence for behavioral relapse prevention (skills training, identifying high-risk situations, rehearsing coping responses) is mixed. It is not that these strategies are ineffective; it is that their effect size is modest compared to pharmacological support, and they add less on top of adequate pharmacotherapy than they add on top of nothing. The practical recommendation is not to substitute behavioral strategies for pharmacological support but to add them: pharmacotherapy as the foundation, behavioral planning as an additional layer.

Using relapse information

Each quit attempt produces data. The relevant questions after a relapse:

1. What was the proximal trigger? Stress, alcohol, social situation, withdrawal symptom, weight gain concern? The trigger identifies the vulnerability to address.
2. What pharmacological support was used? Adequate dose? Sufficient duration? Single vs. combination NRT? Cold turkey? The answer identifies the most modifiable change for the next attempt.
3. When did the relapse occur? First week (withdrawal-driven, suggesting inadequate pharmacological coverage), month 2-3 (situation-driven, suggesting a specific trigger to plan for), later (life event-driven, suggesting extended pharmacotherapy).
4. What was the progression? A single slip that escalated to full relapse within a day suggests the abstinence violation effect; training to reframe a slip as a data point rather than a failure may help. A gradual slide from occasional cigarettes to regular smoking suggests ongoing exposure to triggers.

The answers inform the next attempt. A relapse driven by inadequate pharmacotherapy has a different solution (higher-efficacy method) than a relapse driven by alcohol-related disinhibition (avoid alcohol in early abstinence) or one driven by living with a smoker (address the environmental exposure, or plan for it explicitly).

Most successful quitters have relapsed multiple times before achieving sustained abstinence. The population data shows that successful long-term quitters made a median of 6-30 quit attempts before their final successful one (the range is wide because measurement varies) [1]. This is not evidence of a flawed process. It is the expected trajectory for a chronic condition with a pharmacological basis.

What this means if you’re deciding

If you have relapsed after a previous quit attempt, the relapse is data, not a verdict. The question is what was different about that attempt compared to what you could do next time.

If the previous attempt was unassisted, adding pharmacological support is the highest-yield change. If it was with single NRT, switching to combination NRT or varenicline improves the odds. If the trigger was identifiable (alcohol, stress, a specific person or situation), planning for that trigger on the next attempt is a concrete, addressable step. If the relapse occurred after stopping pharmacological support (weeks 8-12), extending the treatment duration to 24 weeks addresses that specific vulnerability [4].

The framing that matters: quitting is not a test you pass or fail. It is a process with a pharmacological basis, modifiable risk factors, and improving odds on each well-informed attempt. A quit attempt that lasted three weeks and ended in relapse at a party where you were drinking is not a character failure. It is a data point that says: next time, use pharmacological support through the first two months and avoid alcohol for the first four weeks.

For smokers with COPD, the urgency of each attempt is higher because lung function continues declining with each month of continued smoking. Using the highest-efficacy available method (combination NRT or varenicline), extending treatment duration, and planning for known triggers gives the best odds on each attempt. The Lung Health Study showed that sustained quitters had significantly slower lung function decline, and the benefit began from the point of cessation. Each successful quit attempt, even after prior relapses, captures that benefit.

A doctor or pharmacist can help choose the right approach for your health history. The Quitline (1-800-QUIT-NOW) provides free coaching and can sometimes supply NRT.